This inventor holds 1 USPTO granted patent. Top assignee: Universitaet Duisburg-Essen. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: The Innovative Contributions of Fan Steven Zhou
Introduction
Fan Steven Zhou is a notable inventor based in Essen, Germany. He has made significant contributions to the field of immunology through his innovative research and development of antibodies. His work is particularly focused on the anti-CEACAM1 antibody, which has potential applications in medical treatments.
Latest Patents
Fan Steven Zhou holds a patent for an immunostimulatory anti-CEACAM1 antibody. This patent describes an anti-CEACAM1 antibody that includes at least one antibody heavy chain (V) domain with antigen binding sites CDR1, CDR2, and CDR3. Additionally, it features at least one antibody light chain (V) domain with similar antigen binding sites. Notably, the antigen binding site CDR2 has a sequence homology of at least 80% to the amino acid sequence WINTYTGEPT (SEQ ID No. 21). This patent highlights his innovative approach to antibody design and its potential therapeutic applications.
Career Highlights
Fan Steven Zhou is affiliated with the University of Duisburg-Essen, where he conducts his research. His academic background and professional experience have positioned him as a key figure in the field of immunology. His work has garnered attention for its potential impact on medical science and therapeutic development.
Collaborations
Some of his notable coworkers include Karl Lang and Bernhard Singer. Their collaborative efforts contribute to the advancement of research in immunology and antibody development.
Conclusion
Fan Steven Zhou's contributions to the field of immunology through his innovative patent on anti-CEACAM1 antibodies demonstrate his commitment to advancing medical science. His work, in collaboration with esteemed colleagues, continues to pave the way for future developments in therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile